BGI Genomics (300676.SZ) plans to buy back company shares worth 250 million to 500 million yuan.
BGI Genomics (300676.SZ) announced that the company plans to repurchase some of its issued Renminbi ordinary shares (A shares) through centralized bidding using its own funds and self-raised funds. The total amount of the repurchase fund shall not be less than RMB 250 million and not more than RMB 500 million (inclusive). The price range for the repurchased shares shall not exceed RMB 50 per share.
BGI Genomics (300676.SZ) announced that the company plans to use its own funds and self-raised funds to repurchase some of the company's issued Renminbi ordinary shares (A shares) in a centralized bidding manner. The total amount of funds for this repurchase shall be no less than RMB 250 million and no more than RMB 500 million (including the principal, the same below), and the price range for the repurchase shares shall not exceed RMB 50 per share.
Related Articles
Kafelaku Coffee (01869) plans to issue a maximum of 282 million shares for subscription at a discount of approximately 16.5%, raising a net amount of approximately 20.9 million Hong Kong dollars.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.
Independent director Li Liang of EMTEK(Shenzhen)Co., Ltd. (stock code: 300938.SZ) is subject to criminal punishment.
Kafelaku Coffee (01869) plans to issue a maximum of 282 million shares for subscription at a discount of approximately 16.5%, raising a net amount of approximately 20.9 million Hong Kong dollars.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.
Independent director Li Liang of EMTEK(Shenzhen)Co., Ltd. (stock code: 300938.SZ) is subject to criminal punishment.
RECOMMEND
